用于治疗骨髓增生异常综合征的分化诱导剂。 - Suppr | 超能文献

Differentiation-inducing agents in the treatment of myelodysplastic syndromes.

作者信息

Kizaki M, Koeffler H P

机构信息

Division of Hematology/Oncology, UCLA School of Medicine.

出版信息

Semin Oncol. 1992 Feb;19(1):95-105.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Differentiation-inducing agents in the treatment of myelodysplastic syndromes.用于治疗骨髓增生异常综合征的分化诱导剂。

Semin Oncol. 1992 Feb;19(1):95-105.

2

Differentiation therapy in myelodysplastic syndromes.骨髓增生异常综合征的分化治疗

Semin Hematol. 1996 Jul;33(3):236-45.

3

Differentiation therapy.分化疗法

Hematol Oncol Clin North Am. 1992 Jun;6(3):687-706.

4

Differentiation therapy of myelodysplastic syndromes: fact or fiction?骨髓增生异常综合征的分化治疗：事实还是虚构？

Br J Haematol. 1998 Sep;102(5):1124-38. doi: 10.1046/j.1365-2141.1998.00881.x.

5

Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1,25-dihydroxyvitamin D3, and analogs.维甲酸、细胞因子、1,25-二羟基维生素D3及其类似物用于癌症联合化疗的实验基础

J Cell Biochem. 1994 Dec;56(4):427-35. doi: 10.1002/jcb.240560402.

6

5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.5-氮杂胞苷：对造血生长因子难治性反应患者骨髓增生异常综合征的一种替代治疗，病例报告及文献综述

Hawaii Med J. 2004 Jan;63(1):14-6, 25.

7

Azacitine (vidaza) for myelodysplastic syndrome.阿扎胞苷（维达莎）用于治疗骨髓增生异常综合征。

Med Lett Drugs Ther. 2005 Jan 31;47(1201):11.

8

Disseminated varicella-zoster virus infection following azacitidine in a patient with myelodysplastic syndrome.一名骨髓增生异常综合征患者使用阿扎胞苷后发生播散性水痘-带状疱疹病毒感染。

Clin J Oncol Nurs. 2009 Jun;13(3):280-4. doi: 10.1188/09.CJON.280-284.

9

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.批准摘要：阿扎胞苷用于治疗骨髓增生异常综合征亚型。

Clin Cancer Res. 2005 May 15;11(10):3604-8. doi: 10.1158/1078-0432.CCR-04-2135.

10

New drug for bone marrow disease.

FDA Consum. 2004 Jul-Aug;38(4):7.

引用本文的文献

1

The effect of sodium butyrate in combination with ATRA on the proliferation/differentiation of SKM-1.

J Huazhong Univ Sci Technolog Med Sci. 2004;24(4):334-7. doi: 10.1007/BF02861861.

2

A differential screen for ligand-regulated genes: identification of HoxA10 as a target of vitamin D3 induction in myeloid leukemic cells.一种用于筛选配体调节基因的差异筛选方法：鉴定HoxA10为髓系白血病细胞中维生素D3诱导的靶标。

Mol Cell Biol. 1998 Apr;18(4):1911-8. doi: 10.1128/MCB.18.4.1911.